Sri Lanka Import Licence Issuance Process

1. Key takeaways

Entering the Sri Lankan market requires two documents to connect: registration plus an import licence. First the product registration certificate is obtained, then the Licensing Division issues the import licence, and only then can customs clearance proceed. The complete chain runs: appointment of the local agent → (where applicable) Manufacturing Site approval FMSA → product registration PRD → (where applicable) Sample Import Licence SIL and sample testing → MDEC technical evaluation → CEO approval → the Licensing Division issues the registration certificate and the import licence. Each link feeds the next, and a delay in any of them propagates to the clearance date, so the chain is best managed as one schedule rather than as isolated steps. In practice this means the two-document principle governs everything downstream: the registration certificate proves the product is authorised, the import licence proves the shipment is authorised, and customs clearance is lawful only when both are in hand and aligned with the goods being declared.

• The registration certificate and the import licence are two separate documents; neither substitutes for the other.
• The sequence is fixed: register first, obtain the import licence second, then clear customs.
• Foreign manufacturers must appoint a Sri Lankan local MAH as the starting point of the chain.
• FMSA (full route) and PRD follow under GL-034; SIL applies where samples are needed.
• MDEC meets monthly for technical evaluation; decisions go to the CEO for approval.
• The Licensing Division issues both the certificate and the import licence; the Market Control Division supervises imports.

2. Legal basis

The chain is assembled from the NMRA medical device pages, GL-034, and the official descriptions of the bodies involved. The table below lists each stage with its key point and source, in the order of the process.

The table makes the division of labour visible: the review chain — FMSA, PRD, SIL, MDEC, CEO — runs through the technical bodies, while issuance and import supervision sit with the Licensing Division and the Market Control Division respectively. Knowing which body owns which stage determines who to address at each moment of the process. It also explains the rhythm of the chain: because MDEC meets monthly, the technical stages advance in month-sized steps, so the practical planning question for any submission is not only whether the dossier is complete but whether it arrives in time for the next meeting rather than the one after.

3. Expert insights

Insight one: the registration certificate and the import licence are two documents, and neither can replace the other. The order at the rule level is to register first and obtain the import licence second, and the two documents are issued separately by the review chain and by the Licensing Division. Confusing the two — for example, treating the certificate as authority to import — produces a shipment with no lawful basis at the border. Each document answers a different question, and the schedule must give each its own completion date.

Insight two: the Licensing Division handles both the SIL and the import licence. This means the sample stage and the formal import stage sit with the same department, so the cost of connecting them is low; but the status of the two documents must be tracked separately. A single point of contact does not merge the files: the SIL covers samples for testing, while the import licence covers commercial shipments, and treating one as covering the other is a classic clearance error.

Insight three: the import stage is also subject to supervision by the Market Control Division. It is responsible for ensuring that imported medical products meet Sri Lanka’s safety, quality, and regulatory standards, and it cooperates with NMQAL on post-market sampling. This means that even after customs clearance is complete, a consignment may still be drawn for testing. Clearance is therefore the midpoint of the compliance chain, not its end, and the organisation must remain inspection-ready after goods have arrived.

4. Practical recommendations

• GRZAN prepares an import three-piece set for clients: a registration certificate status table (certificate number, validity, coverage), an import licence status table (document number, validity, covered batches), and a sampling response plan (the document pack and contacts for NMQAL testing).
• With these three in place, the connection from customs clearance to market placement runs smoothly, because every handover point in the chain has a document and an owner.
• Confirm before each shipment that the imported product falls within the coverage of the registration certificate and that the import licence is current.
• Track the SIL and the import licence as separate files even though both sit with the Licensing Division.
• Keep the sampling response plan current: the document pack, the responsible contacts, and the laboratory interface for NMQAL testing.
• Follow the Market Control Division’s import regulation requirements and schedule the next renewal and change work against the same calendar.

5. Verification checklist

• □ The product registration certificate has been obtained
• □ The import licence has been processed and is within its validity period
• □ The imported product has been confirmed to fall within the coverage of the registration certificate
• □ A response plan for NMQAL sampling has been established
• □ The import regulation requirements of the Market Control Division are being tracked
• □ The follow-up renewal and change plan has been scheduled

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Sri Lanka. Our team prepares dossiers to NMRA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Regulatory information verified as of 28 October 2026.